Press Release

NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP

NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference

NeoGenomics Reports Fourth Quarter and Full Year 2022 Results

NeoGenomics Schedules its Fourth Quarter and Full Year 2022 Earnings Release for February 23, 2023

RaDaR® Assay Demonstrates Clinical Potential for Helping Oncologists Determine Whether or Not Muscle-Invasive Bladder Cancer Patients Undergo Radical Surgery

NeoGenomics Announces Chief Financial Officer Transition

NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients